Abstract: Breast cancer is the highest incidence and mortality of malignant tumor in women. Recurrence and distant metastasis are the main cause of death. Zoledronic acid (ZOL) has the potential to inhibit bone resorption characteristics mediated by osteoclast, which not only could suppress tumor cell proliferation and start the apoptosis of tumor cells, but also might interfere the adhesion of cancer cells to bone matrices, thereby could inhibit the migration and invasion of tumor cells. In some preclinical studies zoledronic acid has been demonstrated to have the direct anti-tumor effects on breast cancer. There are different therapeutic effects in treatment with zoledronic acid between the premenopausal and post-menopausal patients with breast cancer. This review summarized basic and clinical research progress of the anti-tumor differentiation effect of zoledronic acid in breast cancer.

Key words: breast neoplasms, antineoplastic agents, clinical trial, Zoledronic acid